CDEK
← All drugs Report issue

Raltitrexed

Trade name: Tomudex

Small moleculeexperimental

Raltitrexed is an antimetabolite drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca. — Wikipedia

Clinical trial activity

56 trials · 56 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
45
Phase 3
7
Phase 4
3

Earliest trial started Sep 1, 1993 (NCT00001341)

Timeline

1990s

  1. Jan 1, 1993

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1995

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1
Mol. weight
458.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • arkomédika brand of raltitrexed
  • astrazeneca brand of raltitrexed
  • d1694
  • d 1694
  • d-1694
  • d-1694
  • ici d1694
  • ici-d1694
  • ici-d1694
  • n-(5-(n-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-n-methylamino)-2-thenoyl)-l-glutamic acid
  • ralitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • raltitrexed
  • tomudex
  • tomudex
  • tomudex
  • tomudex
  • tomudex
  • zd-16
  • zd-16
  • zd1694
  • zd 1694
  • zd-1694
  • zd-1694
  • zd-1694
  • zd-1694
  • zeneca brand of raltitrexed

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06652412Phase 2Nov 30, 2024Fudan University
NCT06665087Phase 2Nov 30, 2024Fudan University
NCT06475287Phase 2Jul 20, 2024Fudan University
NCT06441019Phase 2Jul 1, 2024Fudan University
NCT06423937Phase 2May 31, 2024Fudan University
NCT06427005Phase 2Feb 20, 2023Sichuan University
NCT05766605Phase 3Jan 1, 2023Southern Medical University
NCT05701436Phase 3Sep 1, 2022Southern Medical University
NCT05435313Phase 2Jul 12, 2022Fudan University
NCT05426811Phase 1/Phase 2 (Phase 2)Jul 1, 2022Anshan Tumor Hospital, Benxi City hospital of Chinese medicine, China Medical University, Dalian Medical University, The People's Hospital of Liaoning Province
NCT05160896Phase 2Nov 12, 2021Zhejiang University
NCT05007587Early Phase 1 (Phase 1)Jul 1, 2021Chinese Academy of Medical Sciences, Jinhua Central Hospital, Shaoxing People's Hospital, Wenzhou Medical University, Zhejiang University
NCT04582981Phase 2Oct 31, 2020Fudan University, Shanxi Medical University
NCT04597970Phase 2Oct 20, 2020Chinese Academy of Medical Sciences
NCT05148143Phase 2Jun 1, 2020Zhejiang University
NCT04761185Phase 1Jan 1, 2020Fudan University
NCT04241731Phase 2Nov 28, 2019Jiangsu Cancer Institute & Hospital
NCT04581876Phase 2Nov 1, 2019Fudan University
NCT03823079Phase 2Feb 1, 2019Fudan University
NCT03813641Phase 2Jan 22, 2019Shenzhen University
Showing 20 of 56 trials
Page 1 / 3

Organizations

Research & Development (56)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Fudan UniversityAcademic/Hospital161532013
Chinese Academy of Medical SciencesAcademic/Hospital4422015
National Cancer Institute (NCI)Government4211993
Zhejiang UniversityAcademic/Hospital4332015
Dalian Medical UniversityAcademic/Hospital3122016
AstraZenecaFor profit2222002
China Medical UniversityAcademic/Hospital2212016
European Organisation for Research and Treatment of CancerAcademic/Hospital2221999
Nanjing Medical UniversityAcademic/Hospital2222015
People's Liberation Army of ChinaGovernment2112016
PfizerFor profit2012010
Southern Medical UniversityAcademic/Hospital2212022
Wuhan UniversityAcademic/Hospital2112015
Anshan Tumor HospitalAcademic/Hospital1012022
Apices Soluciones S.L.For profit1012012
Beijing Cancer HosptialAcademic/Hospital1112015
Benxi City hospital of Chinese medicineAcademic/Hospital1012022
Centre Georges Francois LeclercAcademic/Hospital1112010
Cornell UniversityAcademic/Hospital1111995
Donghai People's HospitalAcademic/Hospital1012012
56 organizations
Page 1 / 3